Valuation: Entia Biosciences, Inc.

Market Cap 235K 205K 191K 175K 330K 22.48M 335K 2.25M 881K 11.19M 884K 865K 37.52M P/E 2015
-0.97x
P/E 2016 -1.13x
Enterprise Value 1.21M 1.05M 975K 895K 1.69M 115M 1.72M 11.5M 4.51M 57.29M 4.53M 4.43M 192M EV / Sales 2015
8.29x
EV / Sales 2016 9.59x
Free-Float
99.44%
Yield 2015 *
-
Yield 2016 -
1 day-50.00%
1 week-50.00%
Current month-50.00%
1 month-50.00%
3 months-83.33%
6 months-66.67%
Current year-66.67%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0.0001
0.04
1 year 0
Extreme 0.0001
0.04
3 years 0
Extreme 0
0.04
5 years 0
Extreme 0
0.17
10 years 0
Extreme 0
0.39
Manager TitleAgeSince
Chief Executive Officer 69 2017-11-27
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-50.00%-.--%-50.00% 6.81K
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -6.35%+0.95%+55.25%+73.68% 25.04B
Weighted average by Cap. -1.60%+2.03%+79.78%+108.61%

Financials

2015 2016
Net sales 347K 302K 281K 258K 487K 33.12M 494K 3.31M 1.3M 16.49M 1.3M 1.27M 55.28M 265K 231K 215K 197K 372K 25.34M 378K 2.53M 994K 12.62M 997K 975K 42.3M
Net income -2.26M -1.96M -1.83M -1.68M -3.17M -216M -3.22M -21.56M -8.46M -107M -8.49M -8.3M -360M -1.4M -1.21M -1.13M -1.04M -1.96M -133M -1.99M -13.31M -5.22M -66.33M -5.24M -5.13M -222M
Net Debt 255K 222K 206K 190K 358K 24.35M 363K 2.43M 955K 12.12M 958K 937K 40.65M 970K 843K 785K 721K 1.36M 92.59M 1.38M 9.25M 3.63M 46.1M 3.64M 3.56M 155M
Logo Entia Biosciences, Inc.
Entia Biosciences, Inc. develops pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2. The Company also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The Company's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The Company's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
Employees
7
Date Price Change Volume
26-07-27 US$0.000200 -.--% 1,500
  1. Stock Market
  2. Stocks
  3. ERGO Stock